Healthcare Facilities company Artemis Medicare Services announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Net Revenue from Operations increased by 7.3% to Rs 2,414 million from Rs 2,250 million. EBITDA increased by 35.7% to Rs 497 million from Rs 366 million. EBITDA margin at 20.6% compared to 16.3%. PBT increased by 62.6% to Rs 306 million from Rs 188 million with margin of 12.7%. PAT increased by 63.5% to Rs 221 million from Rs 135 million, with margin of 9.2%. H1FY25 Financial Highlights: Net Revenue from Operations increased by 6.9% to Rs 4,646 million from Rs 4,345 million. EBITDA increased by 37.2% to Rs 903 million from Rs 658 million, with margin of 19.4% over 15.1%. PAT increased by 66.0% to Rs 387 million from Rs 233 million, with margin of 8.3% over 5.4%. Devlina Chakravarty, Managing Director of Artemis Medicare Services, said: "We are pleased to announce the strong performance of Q2FY25 and H1FY25, with our continuous focus on all key metrics. We have been able to achieve our best-ever performance with the highest revenue and EBITDA margins, by harnessing economies of scale and improving cost efficiencies. We have also inaugurated the third tower, which will be operationalised in a phase-wise manner to cater to the increasing customer base and further enhance our operational and financial performance. On the Operational front, we concentrated on refining the payer mix and removing bottlenecks, resulting in one of the industry-leading ARPOBs and improvement in margins. Our high revenue share from international patients underscores our role and recognition as a trusted centre for Medical Value Travel. In line with our strategic growth initiatives, the Board has approved to enter into a long term Operations & Management and Medical Services Agreement in Raipur for a 300+ bed super speciality hospital subject to completion of customary closing conditions. This hospital will be operational in approx. one year and will help us extend our reach to central India. We are further exploring more expansion opportunities in the super-speciality segment, enabling us to leverage our brand, strengthen our presence and lay a foundation for future growth." Result PDF